In the US, breast cancer is the most common cancer and the second most common cause of cancer death among women.1 Like other cancers, breast cancer is a heterogeneous disease with various oncogenic drivers.
Idoko Salifu (a), Navneet Singh (b), Maria Berraondo (a), Jordi Remon (c), Stephanie Salifu (d), Eric Severson (a), Angela Quintana (e), Sandra Peir´o (e), Shakti Ramkissoon (a,f), Laura Vidal (a), Isagani Chico (a), Kamal S. Saini (a,g)
a Labcorp Drug Development Inc., Princeton, NJ, USA b Postgraduate Institute of Medical Education and Research, Chandigarh, India c Paris-Saclay University, department of Cancer Medicine, Gustave Roussy, Villejuif, France d Dix Hills, NY, USA e Vall d’Hebron Institute of Oncology, Barcelona, Spain f Department of Pathology, Wake Forest School of Medicine and Comprehensive Cancer Center, Winston-Salem, NC, USA g Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing is a complementary approach to tissue testing, particularly when tissue is not readily available.
Ellen L. Verner, Jennifer B. Jackson. Eric Severson, Kenneth C. Valkenburg, Amy E. Greer, David R. Riley, Mark Sausen, Cynthia Maddox, Paul M. McGregor III, Aanavi Karandikar, Stephanie B. Hastings, Rebecca A. Previs, Venkataprasanth P. Reddy, Taylor J. Jensen, Shakti H. Ramkissoon
Few DNA panels target NRG1 for sequencing. This paper highlights the value of RNA sequencing in OmniSeq for detecting these rare fusions and directing patient treatment.Graphical Summary of RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
Eric Severson, B.R. Achyut, Mary Nesline, Sarabjot Pabla, Rebecca A. Previs, Geoffrey Kannan, Anjen Chenn, Shengle Zhang, Roger Klein, Jeffrey Conroy, Mark Sausen, Pratheesh Sathyan, Kamal S. Saini, Aradhana Ghosh, Taylor J. Jensen, Prasanth Reddy, Shakti H. Ramkissoon
